Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $1,045 MXN
Change Today +27.30 / 2.68%
Volume 1.3K
TEVAN On Other Exchanges
New York
Tel Aviv
As of 4:09 PM 11/25/15 All times are local (Market data is delayed by at least 15 minutes).

teva pharmaceutical-sp adr (TEVAN) Snapshot

Previous Close
Day High
Day Low
52 Week High
08/5/15 - $1,162
52 Week Low
12/2/14 - $800.55
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

teva pharmaceutical-sp adr (TEVAN) Details

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic, specialty, and other pharmaceutical products worldwide. The company operates in two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers generic or branded generic medicines; specialized products, such as sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances; and active pharmaceutical ingredients. The Specialty Medicines segment provides branded specialty medicines for use in central nervous system and respiratory indications, as well as the women’s health, oncology, and other specialty businesses. Its products in the central nervous system area comprise Copaxone for multiple sclerosis; Azilect for the treatment of Parkinson’s disease; Nuvigil and Provigil to treat excessive sleepiness associated with narcolepsy, obstructive sleep apnea, and shift work disorders; Fentora/Effentora and Actiq to treat pain in opioid-tolerant adult patients with cancer; Zecuity for the treatment of migraine in adults; and Amrix for muscle spasm in acute, painful, and musculoskeletal conditions. This segment’s products in the respiratory market include ProAir, QVAR, and Duoresp Spiromax for the treatment of asthma and chronic obstructive pulmonary disease, as well as Treanda, Trisenox, Granix, Synribo, Lonquex, Tevagrastim/Ratiograstim, Myocet, and Eporatio products in the oncology market. This segment also offers a portfolio of products in the women’s health category, which includes ParaGard, Plan B One-Step, and Zoely. In addition, the company provides branded over-the-counter medicines in the categories of cough/cold and allergy, digestive wellness, vitamins, minerals and supplements, analgesics, and skin medications; and sells third-party products, such as medical devices and other miscellaneous items. Teva Pharmaceutical Industries Limited was founded in 1901 and is based in Petach Tikva, Israel.

43,009 Employees
Last Reported Date: 02/9/15
Founded in 1901

teva pharmaceutical-sp adr (TEVAN) Top Compensated Officers

Chief Executive Officer, President, Director ...
Total Annual Compensation: $3.3M
Compensation as of Fiscal Year 2014.

teva pharmaceutical-sp adr (TEVAN) Key Developments

Teva Pharmaceutical Industries Limited and Heptares Therapeutics Enter Agreement to Discover and Develop Novel, Small-Molecule CGRP Antagonists for Treatment of Migraine

Teva Pharmaceutical Industries Limited and Heptares Therapeutics announced that they have entered into a licensing and drug-discovery agreement under which Teva will receive exclusive global rights to develop, manufacture and commercialize novel, small-molecule calcitonin gene-related peptide antagonists discovered by Heptares for the treatment of migraine. Under the terms of the agreement, Heptares will receive an upfront payment of $10 million, research funding, and is eligible to receive additional research, development and commercialization milestone payments of up to $400 million. In addition, Heptares will be eligible to receive royalties on net sales of products resulting from the alliance.

Teva Reports Positive Top-Line Results from Phase III Trials Evaluating Fluticasone Propionate/Salmeterol and Fluticasone Propionate Multidose Dry Powder Inhalers in Patients with Asthma

Teva Pharmaceutical Industries Ltd. announced positive top-line results from three Phase III clinical studies designed to evaluate the efficacy and safety of fluticasone propionate/salmeterol, a combination inhaled corticosteroid (ICS) and long-acting beta agonist (LABA) delivered via a multidose dry powder inhaler (MDPI) and fluticasone propionate, an ICS monotherapy delivered via a MDPI in adolescent and adult patients with asthma. Top-line data showed that the studies met their primary endpoints. Importantly, the studies also showed similar overall safety profiles as compared to therapies in the corresponding drug classes. Fluticasone propionate/salmeterol MDPI demonstrated, in the double-blind studies, clinically relevant and greater benefit at all doses (50/12.5, 100/12.5, and 200/12.5 mcg BID nominal delivered doses) versus placebo and versus respective monotherapy (fluticasone propionate) in the improvement of lung function as measured by the change from baseline in trough Forced Expiratory Volume in one second (FEV) at the 12-week trial period and standardized baseline-adjusted area under the effect curve FEV from time 0 to 12 hours post dose at Week 12. This initial set of results shows the adverse event profile of fluticasone propionate/salmeterol MDPI was comparable to fluticasone propionate monotherapy and placebo. Fluticasone propionate MDPI also demonstrated clinically relevant and greater benefit at all doses (50, 100, and 200 mcg BID nominal delivered doses) versus placebo in the improvement of lung function, in the double-blind studies. The initial set of results shows the adverse event profile of fluticasone propionate MDPI was comparable to placebo. The majority of adverse events were mild to moderate in severity. There were no drug-related deaths across any of the trials. Further analyses of additional efficacy and safety data are ongoing. Regulatory submissions for both fluticasone propionate/salmeterol MDPI and fluticasone propionate MDPI in the U.S. are planned for 2016.

Drug makers Reportedly Seeks Acquisition Of Products To Be Hived Off Teva Pharmaceutical

Drug makers reportedly are seeking acquisition of tens of products to be hived off in the US by Teva Pharmaceutical Industries Limited (NYSE:TEVA). Cipla Limited (NSEI:CIPLA) and Glenmark Pharmaceuticals Ltd. (BSE:532296) are among some 30 companies bidding for tens of products to be hived off in the US, the world's biggest pharma market, as part of Teva Pharmaceutical Industries's acquisition of Allergan plc (NYSE:AGN)'s generics business. Industry sources indicated to ET that Indian drug makers will be keen to buy the generic portfolio on offer, which could be valued at a minimum of $500 million. By regulations of the US Federal Trade Commission, Teva Pharmaceutical Industries needs to undergo a divestiture process for the overlapping products as part of its deal to ensure fair market competition. "In the second round about 20 companies are expected to figure and the actual valuations of the bids will be known during that process," one industry source said. While it could not be confirmed immediately, Cadila Healthcare Limited (BSE:532321) and Dr. Reddy's Laboratories Ltd. (BSE:500124)'s may also form part of the list that made it to the second round. In response to questions from ET, a Cipla spokesperson said the company does not comment on any product or partner discussions. "As a pharmaceutical company we are constantly in discussions with multiple parties on potential collaboration opportunities - in line with our aspiration to drive access and ensure availability of high quality, affordable medicines," the person said. Glenmark too declined to comments.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
TEVAN:MM $1,045.29 MXN +27.30

TEVAN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Abbott Laboratories $45.41 USD -0.04
AbbVie Inc $60.29 USD -0.84
AstraZeneca PLC 4,500 GBp +36.50
Biogen Inc $292.30 USD +3.15
Eli Lilly & Co $83.74 USD -0.14
View Industry Companies

Industry Analysis


Industry Average

Valuation TEVAN Industry Range
Price/Earnings 30.2x
Price/Sales 2.7x
Price/Book 2.3x
Price/Cash Flow 33.8x
TEV/Sales 2.4x

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact TEVA PHARMACEUTICAL-SP ADR, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at